CytoMed Therapeutics Accounts Payable

CytoMed Therapeutics (GDTC) currently reports a accounts payable of $120K as of December 2025. That compares with $28K in the prior-year period — up 340.5% year over year. Use the charts on this page to explore CytoMed Therapeutics's accounts payable history and peer comparisons.

CytoMed Therapeutics's accounts payable increased from $28K to $120K — a 340.5% year-over-year increase (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

CytoMed Therapeutics reported $120K in accounts payable as of December 2025. That compares with $28K in the prior-year period — up 340.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $120K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for CytoMed Therapeutics, and consider following GDTC for alerts when major investors trade the stock.